Compare PLTK & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLTK | IMTX |
|---|---|---|
| Founded | 2010 | N/A |
| Country | Israel | Germany |
| Employees | N/A | 407 |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2020 | N/A |
| Metric | PLTK | IMTX |
|---|---|---|
| Price | $3.40 | $11.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $5.04 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 1.0M | 442.1K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | ★ 11.46% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,755,400,000.00 | N/A |
| Revenue This Year | $2.60 | N/A |
| Revenue Next Year | $2.23 | $25.91 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.08 | N/A |
| 52 Week Low | $2.64 | $4.93 |
| 52 Week High | $5.05 | $12.41 |
| Indicator | PLTK | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.47 | 51.75 |
| Support Level | $3.36 | $9.05 |
| Resistance Level | $3.81 | $11.54 |
| Average True Range (ATR) | 0.19 | 0.60 |
| MACD | -0.04 | -0.06 |
| Stochastic Oscillator | 20.49 | 50.85 |
Playtika Holding Corp is engaged in developing mobile games. Some of its games include Board Kings, House of Fun, Poker Heat, Slotomania, and Bingo Blitz. The company has built live game operations services and a proprietary technology platform to support its portfolio of games. It derives revenue from the sale of virtual items associated with online games. Geographically, the group has a business presence in the USA, EMEA, APAC, and Other regions of which key revenue is derived from the USA. The company offers both Mobile and Web-based platforms.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.